| |
Are you giving healthcare decision makers the information they need about your product? Learn how to engage the right customers via the right channels, and reach providers across multiple touchpoints here. 
|
|
Eisai and Biogen’s Alzheimer’s disease candidate lecanemab hit its primary trial endpoint, slowing cognitive decline by 27%—a big boost as they head toward an FDA accelerated approval decision in January. While Eli Lilly’s latest Type 2 diabetes launch and obesity hopeful Mounjaro is in the running to become “the biggest drug ever,” an approval for donanemab—the company’s antibody for Alzheimer’s disease—would simply be “icing on the cake,” according to analysts. And though a lot has changed since we last ranked the most productive biopharma companies in 2016—with an international pandemic and a few megamergers in between—their numbers are up in our special report, with nine out of 10 companies posting over $1 million in revenue for every employee. |
|
Tuesday, October 4, 2022 | 2pm ET / 11am PT In this webinar we will cover the challenges that this collaboration aims to solve and how the partnership is poised to enable significant scientific outcomes. We will also take your questions live about this exciting advancement. Register now. 
|
|
| By Nick Paul Taylor,Gabrielle Masson Eisai’s phase 3 clinical trial of Biogen-partnered Alzheimer’s disease candidate lecanemab has hit its primary and key secondary endpoints. The result, which analysts called a “major surprise,” gives a big boost to the partners as they head toward an accelerated approval decision in January. |
|
|
|
By Fraiser Kansteiner With Eli Lilly’s latest Type 2 diabetes launch and obesity hopeful in the running to become “the biggest drug ever,” an approval for donanemab—the company’s experimental antibody effort against Alzheimer’s disease—would simply be “icing on the cake” for investors. That's according to analysts at UBS. |
By Angus Liu,Zoey Becker,Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky A lot has changed since we last ranked the most productive biopharma companies with numbers from 2016. Two firms lost their status as standalone companies while boosting their acquirers' positions. This year's ranking also unsurprisingly includes COVID-19 superstars and a couple Big Biotechs. |
By Andrea Park Philips’ respiratory device-focused Respironics business has been in the hot seat for well over a year now, ever since it identified a potentially fatal safety issue with the sound-muffling foam of around 5.5 million of its CPAP and BiPAP machines and other ventilators. |
|
Tuesday, October 4, 2022 | 1pm ET / 10am PT This panel will discuss leveraging technology and home health solutions to augment existing points of care between patients and their clinical care team to improve the patient experience, drive more scientific rigor to data generation and achieve timely endpoint capture. Register now. 
|
|
By Angus Liu In a decision that has largely flown under the radar, AstraZeneca and Merck & Co. have started pulling Lynparza’s use in heavily pretreated BRCA-mutated advanced ovarian cancer patients, similar to what GSK and Clovis are doing for their own PARP inhibitors. |
By Nick Paul Taylor Good, but not good enough. That is the verdict AstraZeneca reached after seeing phase 2b data on its Ionis Pharmaceuticals-partnered cholesterol drug ION449, which comfortably beat placebo but fell short of the bar for further development. |
By Zoey Becker A year after another similar lawsuit, Eli Lilly faces new allegations from the U.S. Equal Employment Opportunity Commission (EEOC) that it intentionally didn't hire older workers for sales representative positions. The company denies the allegations. |
By Nick Paul Taylor Pfizer is finally nearly ready to resume dosing in its phase 3 hemophilia A gene therapy trial. Six months after the FDA lifted the clinical hold on the study, trial sites are set to resume enrollment with a view to restarting dosing in October. |
By Zoey Becker While novel therapy launches are a staple for the industry, a new report from Evaluate Vantage shows that having a few megablockbusters can provide more value than a wide slate of launches. At least, that's the case for Eli Lilly and Novartis over the last five years. |
By Helen Floersh Researchers have identified a protein complex inside neutrophils that appears to act as a gatekeeper for a highly inflammatory form of exocytosis. |
By Angus Liu Even as Novartis works to separate Sandoz, the Swiss parent hasn't stopped making deals for the outgoing generics subsidiary. The company is selling a plant that makes finished drug products to a Chinese CDMO for $15.1 million. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk with many of the Fierce 15 honorees to find out what makes them unique. We also share highlights from the Fierce Biotech Summit on gene editing innovations and battling biotech's bear market. |
|
|---|
|
|
|
Thursday, October 6, 2022 | 11am ET / 8am PT Join this webinar to hear about strategies for developing patient-centric trial designs, methods for alleviating participant burden throughout a trial, and practical guidance on operationalizing your study for patient-centricity. Register now. 
|
|
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
Executive Summary How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign |
Research Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
Research TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn |
| |
|
